Regencell Bioscience Holdings (RGC) Fair Value & Analysis
Healthcare · US · Market cap $11.4B
Regencell Bioscience Holdings
RGC · US
Fair value as of: Jul 18, 2026
From 3 valuation models · updated today
Fair value updated Jul 18, 2026, revised from $0.0400 to $0.4900 (+1,125.0%) since Jun 24, 2026. Share price −66.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $4.78 – $52.88 · fair‑value band $0.4500 – $0.5400 · the $5.02 price screens above the $0.4900 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Regencell Bioscience Holdings (RGC) currently trades at $5.02, while our model-based Fair Value estimate is $0.4900, implying the stock looks roughly 90.2% overvalued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
The balance sheet holds a net cash position of $1.9M. Fundamentals as of Jul 18, 2026
Our scenario range runs from $0.4500 (bear case) to $0.5400 (bull case); at $5.02, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -90%, RGC screens richer than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Revenue & earnings trend
FY2020 – FY2025 · reported fiscal years
Regencell Bioscience Holdings reported revenue of $0 in FY2024 versus $0 in FY2020. Reported net income was −$3.6M in FY2025.
Is RGC fairly valued? → Check now
Recent news
- DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
- REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to
- Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
- RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| Lupin Limited LUPIN | ₹2,247 | ₹2,697 | +20% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Regencell Bioscience Holdings (RGC) undervalued?
What is the fair value of RGC?
What is the quality score of RGC?
What is the net profit margin of RGC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Regencell Bioscience Holdings analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.